NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

Nanobiotix SA

17/04/2023 21:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230417:nGNEbh2Gm7&default-theme=true


Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April
25, 2023

PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX
(https://www.globenewswire.com/Tracker?data=qrdCycXNwDrckDuU6hi2rw71_Zcp9__rYAvzX5LBt-nec7HoObx-XwOO3kO8MEPbkpSJem9piwLRXfJiNISOlQ==)
(Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-stage
clinical biotechnology company pioneering physics-based approaches to expand
treatment possibilities for patients with cancer, today announces it will
issue its financial results for full-year ending December 31, 2022 and provide
an operational update, on Monday, April 24, 2023, after the close of the US
market.

This release will be followed by a conference call and live audio webcast on
Tuesday, April 25, 2023, at 2:00 PM CEST/8:00 AM EDT, prior to the open of
the US market. During the call, Laurent Levy, chief executive officer, and
Bart van Rhijn, chief financial officer, will briefly review the Company’s
year-end results and provide an update on business activities before taking
questions from analysts and investors.

Details for the call are as follows:

Live (US): 1-877-423-9813

Live France: 0 800 912 848

Live (international): 1-201-689-8573

Conference ID: 13738121

Call me™: click here
(https://www.globenewswire.com/Tracker?data=1qnH_elEGV_ea95a1uoDxdVVMsSfqAD_uEsofQPOZFt_PY950WGWj6jqfThVezXIrWz_ZvX-yJ8NpeV39w6egdiTmubz5lIeWp0DKJ9JMShhMbyKcbrP9bbNuxIHe1Ok5g86ap5t5EJ53FXGFjOw-XnVJbMSPVVHpyiVwvKt5yw=)

Participants can use guest dial-in numbers above and be answered by an
operator or they can click the Call me™ link for instant telephone access
to the event (dial-out). The Call me™ link will be made active 15 minutes
prior to scheduled start time. A live webcast of the call may be accessed by
visiting the investors section of the Company’s website at
www.nanobiotix.com. It is recommended to join 10 minutes prior the event
start. A replay of the webcast will be available shortly after the conclusion
of the call and will be archived on the Company’s website.

Participants are invited to email their questions in advance to
investors@nanobiotix.com.

***

About NANOBIOTIX: 
Nanobiotix is a late-stage clinical biotechnology company pioneering
disruptive, physics-based therapeutic approaches to revolutionize treatment
outcomes for millions of patients; supported by people committed to making a
difference for humanity. The company’s philosophy is rooted in the concept
of pushing past the boundaries of what is known to expand possibilities for
human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The
company also has subsidiaries in Cambridge, Massachusetts (United States),
France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris
since 2012 and on the Nasdaq Global Select Market in New York City since
December 2020.

Nanobiotix is the owner of more than 20 patent families associated with three
(3) nanotechnology platforms with applications in 1) oncology; 2)
bioavailability and biodistribution; and 3) disorders of the central nervous
system. The company's resources are primarily devoted to the development of
its lead product candidate–NBTXR3—which is the product of its proprietary
oncology platform and has already achieved market authorization in Europe for
the treatment of patients with soft tissue sarcoma under the brand name
Hensify(®).

For more information about Nanobiotix, visit us at www.nanobiotix.com or
follow us on LinkedIn
(https://www.globenewswire.com/Tracker?data=dOE6nwh0dWDvZteuE-EBHy8QBHiuH4ZkJrQqUU_X-9I10bT42P63zTDUn_L73hY03PnfbM9E3d_02a0yDe0qh9usZy5bHp1a_JIpacNYksw=)
and Twitter
(https://www.globenewswire.com/Tracker?data=_6V61t3dveLd9b3Bm8vtvHYUG_jXVKDgP6t01heDNKwPDyyUnezUSfuURtfRZEV74z5C65amZVRRwIpfMLa-zw==)

Contacts

 Nanobiotix                                                                                                                                                                                                                 
 Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com         Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com    
 Media Relations                                                                                                                                                                                                            
 FR – Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79 97 51 plgermain@ulysse-communication.com    Global – LifeSci Advisors Ligia Vela-Reid +44 (0) 7413825310 Lvela-reid@lifesciadvisors.com                    

Attachment
*     2023-04-17 -- NBTX -- 4Q & FY22 Save-the-Date -- FINAL -- English
(https://ml.globenewswire.com/Resource/Download/53b909f6-6b6b-4477-9caf-d12efde9e005)